REDONDO BEACH, CA--(Marketwired - Nov 29, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article covering how Cell MedX Corp. (OTCQB: CMXC) has improved upon microcurrent technology with eBalance Pro and its progress towards commercialization.
Microcurrent therapy uses extremely low-level electrical currents that promote general wellness and alleviate complications associated with certain medical conditions. On a cellular level, the technology stimulates a dramatic increase in ATP (adenosine triphosphate) production and protein synthesis that accelerates healing and increases blood flow. This translates into decreased inflammation, reduced pain, and other beneficial effects for those suffering from a number of potentially serious health conditions.
This approach is a natural alternative to conventional therapies such as pharmaceuticals and surgical interventions. For example, using microcurrent therapies to reduce pain has the potential to reduce the excessive usage of opioid medications, as well as treat conditions for which there are no conventional therapies -- such as fibromyalgia or diabetes -- where existing standard-of-care options only slightly reduce complications.
Cell MedX Corp. is pioneering a new microcurrent therapy device called eBalance that uses proprietary software to read the body's response to the microcurrents being applied, and uses this information to fine-tune a range of electrical frequencies designed to target specific conditions. The company believes that its technology has the potential to address the complications associated with a growing list of medical conditions.
Cell MedX is initially focusing its clinical protocols on safely studying the effects of its eBalance Pro device on diabetes and related complications. The observations and testimonials resulting from the company's early observations are currently being reported on Cell MedX's website on an ongoing basis, but investors will have to wait for the results from its initial observational clinical trials to determine the efficacy profile anticipated for the technology.
Cell MedX plans to begin observational clinical trials early next year with the goal of obtaining Health Canada approval to use eBalance Pro as a medical device for the treatment of diabetes and related complications. While the company is moving to obtain approval from Health Canada, similar activities are under way in Europe and Asia, and as data becomes available management believes it will be able to more readily develop an FDA approval pathway for the U.S. marketplace.
Follow the link to read the full article: http://analysis.secfilings.com/articles/130-cell-medx-cmxc-advances-the-power-of-microcurrents
Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. In particular, Cell MedX Corp. has not yet begun its clinical trials, which are pending Health Canada approval. There is no assurance that the results of Cell MedX Corp.'s clinical observational trials will be successful, or that it will be able to obtain licensing or approval from Health Canada, the FDA or any other regulatory agencies. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC has been compensated $1,000 for the production and dissemination of this article. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.